Publication:
Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC)

Loading...
Thumbnail Image

Date

2016-06

Authors

Puerta, JM
Jiménez Velasco, A
García, MJ
Molina, JR
Ruiz, C
Ferrer, C
Durán, MS
Simón, I
Clavero, E
Avellaneda, MC

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Ferrata Storti Foundation
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinib on ENESTnd and Dasision clinical trials.

Description

MeSH Terms

Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Azoles::Thiazoles::Dasatinib
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides::Imatinib Mesylate
Medical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Registries

DeCS Terms

CIE Terms

Keywords

Dasatinib, Humanos, Mesilato de imatinib, Leucemia mielogenosa crónica BCR-ABL positiva, Pirimidinas, Sistema de registros, Andalucía

Citation

Puerta JM, Jiménez Velasco A, García MJ, Molina JR, Ruiz C, Ferrer C, et al.Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC). Haematologica. 2016; 101(s1).PB1820